BR112013026539A2 - composições nutricionais que têm a-hica e a-cetoglutarato e métodos de uso das mesmas - Google Patents
composições nutricionais que têm a-hica e a-cetoglutarato e métodos de uso das mesmasInfo
- Publication number
- BR112013026539A2 BR112013026539A2 BR112013026539A BR112013026539A BR112013026539A2 BR 112013026539 A2 BR112013026539 A2 BR 112013026539A2 BR 112013026539 A BR112013026539 A BR 112013026539A BR 112013026539 A BR112013026539 A BR 112013026539A BR 112013026539 A2 BR112013026539 A2 BR 112013026539A2
- Authority
- BR
- Brazil
- Prior art keywords
- nutritional compositions
- methods
- ketoglutarate
- hica
- nutritional
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 6
- 235000016709 nutrition Nutrition 0.000 title abstract 6
- 238000000034 method Methods 0.000 title abstract 4
- 102000008934 Muscle Proteins Human genes 0.000 abstract 2
- 108010074084 Muscle Proteins Proteins 0.000 abstract 2
- 108010046377 Whey Proteins Proteins 0.000 abstract 2
- 102000007544 Whey Proteins Human genes 0.000 abstract 2
- 235000021119 whey protein Nutrition 0.000 abstract 2
- LVRFTAZAXQPQHI-RXMQYKEDSA-N (R)-2-hydroxy-4-methylpentanoic acid Chemical compound CC(C)C[C@@H](O)C(O)=O LVRFTAZAXQPQHI-RXMQYKEDSA-N 0.000 abstract 1
- -1 1-carnitine Substances 0.000 abstract 1
- KPGXRSRHYNQIFN-UHFFFAOYSA-N 2-oxoglutaric acid Chemical compound OC(=O)CCC(=O)C(O)=O KPGXRSRHYNQIFN-UHFFFAOYSA-N 0.000 abstract 1
- OXTNCQMOKLOUAM-UHFFFAOYSA-N 3-Oxoglutaric acid Chemical compound OC(=O)CC(=O)CC(O)=O OXTNCQMOKLOUAM-UHFFFAOYSA-N 0.000 abstract 1
- RHGKLRLOHDJJDR-BYPYZUCNSA-N L-citrulline Chemical compound NC(=O)NCCC[C@H]([NH3+])C([O-])=O RHGKLRLOHDJJDR-BYPYZUCNSA-N 0.000 abstract 1
- RHGKLRLOHDJJDR-UHFFFAOYSA-N Ndelta-carbamoyl-DL-ornithine Natural products OC(=O)C(N)CCCNC(N)=O RHGKLRLOHDJJDR-UHFFFAOYSA-N 0.000 abstract 1
- JAZBEHYOTPTENJ-JLNKQSITSA-N all-cis-5,8,11,14,17-icosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O JAZBEHYOTPTENJ-JLNKQSITSA-N 0.000 abstract 1
- LVRFTAZAXQPQHI-UHFFFAOYSA-N alpha-hydroxyisocaproic acid Natural products CC(C)CC(O)C(O)=O LVRFTAZAXQPQHI-UHFFFAOYSA-N 0.000 abstract 1
- 235000001014 amino acid Nutrition 0.000 abstract 1
- 150000001413 amino acids Chemical class 0.000 abstract 1
- 229960004203 carnitine Drugs 0.000 abstract 1
- 230000015556 catabolic process Effects 0.000 abstract 1
- 235000013477 citrulline Nutrition 0.000 abstract 1
- 229960002173 citrulline Drugs 0.000 abstract 1
- 229960005135 eicosapentaenoic acid Drugs 0.000 abstract 1
- JAZBEHYOTPTENJ-UHFFFAOYSA-N eicosapentaenoic acid Natural products CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O JAZBEHYOTPTENJ-UHFFFAOYSA-N 0.000 abstract 1
- 235000020673 eicosapentaenoic acid Nutrition 0.000 abstract 1
- 230000002708 enhancing effect Effects 0.000 abstract 1
- 239000000835 fiber Substances 0.000 abstract 1
- 239000004615 ingredient Substances 0.000 abstract 1
- 230000014759 maintenance of location Effects 0.000 abstract 1
- 239000000693 micelle Substances 0.000 abstract 1
- 239000002773 nucleotide Substances 0.000 abstract 1
- 125000003729 nucleotide group Chemical group 0.000 abstract 1
- 235000013406 prebiotics Nutrition 0.000 abstract 1
- 238000001243 protein synthesis Methods 0.000 abstract 1
- 208000001076 sarcopenia Diseases 0.000 abstract 1
- 230000014616 translation Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/115—Fatty acids or derivatives thereof; Fats or oils
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/115—Fatty acids or derivatives thereof; Fats or oils
- A23L33/12—Fatty acids or derivatives thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/175—Amino acids
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/745—Bifidobacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/062—Ascomycota
- A61K36/064—Saccharomycetales, e.g. baker's yeast
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/06—Anabolic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02E—REDUCTION OF GREENHOUSE GAS [GHG] EMISSIONS, RELATED TO ENERGY GENERATION, TRANSMISSION OR DISTRIBUTION
- Y02E10/00—Energy generation through renewable energy sources
- Y02E10/70—Wind energy
- Y02E10/72—Wind turbines with rotation axis in wind direction
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Molecular Biology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physical Education & Sports Medicine (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Rheumatology (AREA)
- Pediatric Medicine (AREA)
- Urology & Nephrology (AREA)
- Neurology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161476345P | 2011-04-18 | 2011-04-18 | |
| PCT/EP2012/057095 WO2012143405A1 (en) | 2011-04-18 | 2012-04-18 | Nutritional compositions having alpha-hica and alpha-ketoglutarate |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112013026539A2 true BR112013026539A2 (pt) | 2016-12-27 |
Family
ID=45976400
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112013026706A BR112013026706A2 (pt) | 2011-04-18 | 2012-04-18 | composições nutricionais compreendendo ácido alfa-hidroxi-isocaproico |
| BR112013026539A BR112013026539A2 (pt) | 2011-04-18 | 2012-04-18 | composições nutricionais que têm a-hica e a-cetoglutarato e métodos de uso das mesmas |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112013026706A BR112013026706A2 (pt) | 2011-04-18 | 2012-04-18 | composições nutricionais compreendendo ácido alfa-hidroxi-isocaproico |
Country Status (13)
| Country | Link |
|---|---|
| US (4) | US20140056862A1 (enExample) |
| EP (4) | EP2699112A1 (enExample) |
| JP (4) | JP2014511890A (enExample) |
| CN (4) | CN103458710A (enExample) |
| AU (4) | AU2012244751A1 (enExample) |
| BR (2) | BR112013026706A2 (enExample) |
| CA (4) | CA2831165A1 (enExample) |
| MX (4) | MX2013012230A (enExample) |
| PH (4) | PH12013502012A1 (enExample) |
| RU (4) | RU2013151083A (enExample) |
| SG (4) | SG194028A1 (enExample) |
| WO (4) | WO2012143402A1 (enExample) |
| ZA (4) | ZA201308606B (enExample) |
Families Citing this family (65)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL2583566T3 (pl) * | 2011-10-21 | 2016-01-29 | Nestec Sa | Micele serwatkowego białka do zwiększania masy mięśni i sprawności |
| EP2583563A1 (en) * | 2011-10-21 | 2013-04-24 | Nestec S.A. | Whey protein micelles against muscle atrophy and sarcopenia |
| ITBO20120226A1 (it) * | 2012-04-24 | 2013-10-25 | Alfa Wassermann Spa | Composizioni comprendenti ornitina alfa-chetoglutarato, processi per il loro ottenimento e il loro uso. |
| CN103783532B (zh) * | 2012-10-29 | 2016-06-08 | 杭州纽曲星生物科技有限公司 | 一种抗老年性肌肉衰减的复合蛋白质粉及其制备方法 |
| CA2909211C (en) * | 2013-04-15 | 2021-06-22 | Nestec S.A. | Use of whey protein in combination with electrical muscle stimulation |
| ES2636479T3 (es) * | 2013-06-10 | 2017-10-05 | N.V. Nutricia | Conservación muscular en el adulto con sobrepeso u obesidad durante un programa de pérdida de peso |
| US9878004B2 (en) | 2013-09-25 | 2018-01-30 | Axcella Health Inc. | Compositions and formulations for treatment of gastrointestinal tract malabsorption diseases and inflammatory conditions and methods of production and use thereof |
| AU2014333977B2 (en) | 2013-10-09 | 2019-12-19 | Société des Produits Nestlé S.A. | Compositions comprising citrulline and leucine and their use in the treatment of diabetes and metabolic syndrome |
| CN103637212B (zh) * | 2013-12-13 | 2014-12-24 | 广东省农业科学院蚕业与农产品加工研究所 | 一种具有降血脂作用的管饲临床营养品及其制备方法 |
| EP3115047B1 (en) * | 2014-03-07 | 2020-05-06 | Ajinomoto Co., Inc. | Debility preventative |
| WO2015137387A1 (ja) * | 2014-03-11 | 2015-09-17 | 協和発酵バイオ株式会社 | 筋肉増強剤 |
| MX2016012427A (es) | 2014-03-26 | 2017-04-27 | Abbott Lab | Suplemento alimenticio en polvo. |
| US20190054093A1 (en) * | 2014-04-04 | 2019-02-21 | Nektium Pharma Sl | Treatment of sarcopenia with ecdysteroids |
| WO2015160262A1 (en) * | 2014-04-16 | 2015-10-22 | Amerikal Nutraceutical Corp | Anti-aging composition |
| MX2016015973A (es) * | 2014-06-03 | 2017-03-08 | Abbott Lab | Mezclas de proteinas basadas en papa y composiciones nutricionales con proteina de patata. |
| US11102994B2 (en) * | 2014-08-21 | 2021-08-31 | Clearfast Inc. | Pre-operative carbohydrate-rich beverage composition and methods of treatment |
| WO2016044167A1 (en) * | 2014-09-15 | 2016-03-24 | Abbott Laboratories | Methods for increasing muscle strength and mobility in subjects experiencing significant physical inactivity using gamma linolenic acid |
| ES2960218T3 (es) * | 2014-10-14 | 2024-03-01 | Nestle Sa | Mejora en la funcionalidad del músculo de hombres ancianos |
| US11040022B2 (en) | 2015-02-05 | 2021-06-22 | William H. Cross, III | Compositions and methods for pain relief |
| NL2015032B1 (en) * | 2015-06-26 | 2017-01-24 | Vitalnext B V | Compositions and methods for the treatment of malnutrition. |
| US10674746B2 (en) | 2015-10-27 | 2020-06-09 | Cytozyme Animal Nutrition, Inc. | Animal nutrition compositions and related methods |
| CN108473384A (zh) | 2015-10-27 | 2018-08-31 | 细胞酶动物营养品公司 | 动物营养成分及相关方法 |
| RU2614881C1 (ru) * | 2015-12-29 | 2017-03-30 | Общество с ограниченной ответственностью "Мобильный доктор" | Комплекс биологически активных веществ, защищающих спортсменов от перетренированности |
| EP3397960B1 (en) * | 2015-12-30 | 2020-01-29 | Société des Produits Nestlé S.A. | Method for determining fat free body mass |
| US10912323B2 (en) | 2016-02-29 | 2021-02-09 | Abbott Laboratories | Nutritional supplement powder |
| US11612632B2 (en) | 2017-04-25 | 2023-03-28 | William H. Cross, III | Compositions and methods for treatment of prediabetes |
| ES2851923T3 (es) * | 2016-05-20 | 2021-09-09 | Nestle Sa | Triglicéridos de cadena intermedia para el tratamiento de enfermedad degenerativa de la válvula mitral en animales de compañía |
| CN106213522A (zh) * | 2016-08-05 | 2016-12-14 | 郑家福 | 营养保健品 |
| RU2635373C1 (ru) * | 2016-08-25 | 2017-11-13 | Федеральное государственное бюджетное образовательное учреждение высшего образования "Национальный исследовательский Мордовский государственный университет им. Н.П. Огарёва" | Биологически активная добавка для повышения общей работоспособности |
| RU2762607C2 (ru) | 2016-09-13 | 2021-12-21 | Аллерган, Инк. | Стабилизированные небелковые композиции клостридиального токсина |
| CN109982585B (zh) * | 2016-11-16 | 2024-03-15 | 费森尤斯卡比德国有限公司 | 用于患有肌少症和/或衰弱症的患者或肌少症前期和/或衰弱症前期患者的疗法中的用途的营养组合物 |
| JOP20190146A1 (ar) | 2016-12-19 | 2019-06-18 | Axcella Health Inc | تركيبات حمض أميني وطرق لمعالجة أمراض الكبد |
| KR20180081361A (ko) * | 2017-01-06 | 2018-07-16 | 연세대학교 산학협력단 | 인돌-3-카비놀 또는 이의 약학적으로 허용 가능한 염을 유효성분으로 포함하는 근육 질환 예방 또는 치료용 조성물 |
| US12213952B1 (en) | 2017-03-09 | 2025-02-04 | Heh Research & Development Services, Inc. | Biologic enhancement formulation |
| WO2020106746A1 (en) * | 2018-11-19 | 2020-05-28 | Heh Research & Development Services, Inc. | Biologic enhancement formulation |
| US20200188327A1 (en) * | 2017-04-25 | 2020-06-18 | Buck Institute For Research On Aging | Formulations for extending lifespan and healthspan |
| SG11201912551UA (en) | 2017-06-21 | 2020-01-30 | Abbott Lab | Methods for increasing growth of beneficial bacteria in the gastrointestinal tract |
| CN107242572A (zh) * | 2017-07-06 | 2017-10-13 | 广州彤博士健康科技有限公司 | 营养补充剂及制备方法 |
| BR112020002419A2 (pt) | 2017-08-14 | 2020-07-28 | Axcella Health Inc. | aminoácido para o tratamento de doença do fígado |
| CN107616505B (zh) * | 2017-10-24 | 2020-12-25 | 精晶药业股份有限公司 | 一种含有鸟氨酸酮戊二酸的保健品及其制备方法 |
| PL238310B1 (pl) * | 2017-10-31 | 2021-08-09 | Top Energy Set Spolka Z Ograniczona Odpowiedzialnoscia | Preparat leczniczy oraz sposób jego uzyskiwania |
| US11304971B2 (en) | 2018-01-31 | 2022-04-19 | William H. Cross, III | Metformin compositions and methods for treatment of diabetes |
| US11351188B2 (en) | 2018-01-31 | 2022-06-07 | William H. Cross, III | Folic compositions and methods for treatment of diabetic neuropathies |
| US11154523B2 (en) | 2018-01-31 | 2021-10-26 | William H. Cross, III | Compositions and methods for treatment of diabetic neuropathies |
| US12329818B2 (en) | 2018-02-22 | 2025-06-17 | William H. Cross, III | Topical compositions and methods for treatment of diabetic neuropathies |
| EP3810123A1 (en) | 2018-06-20 | 2021-04-28 | Axcella Health Inc. | Compositions and methods for the treatment of fat infiltration in muscle |
| SG11202102204PA (en) | 2018-09-25 | 2021-04-29 | Ponce De Leon Health Designated Activity Company | Process of making calcium alpha-ketoglutarate |
| KR102171518B1 (ko) * | 2019-02-21 | 2020-10-29 | 한양대학교 에리카산학협력단 | 지골피 추출물을 유효성분으로 함유하는 근 위축 예방 또는 치료용 조성물 |
| WO2020240500A1 (en) * | 2019-05-31 | 2020-12-03 | Societe Des Produits Nestle Sa | Mct-based nutrition blend for providing health benefits in animals |
| CA3142781A1 (en) * | 2019-06-10 | 2020-12-17 | Buck Institute For Research On Aging | Methods and compositions for altering senescence associated secretory phenotype |
| CN110226756A (zh) * | 2019-06-18 | 2019-09-13 | 山东理工大学 | 预防和缓解2型糖尿病患者肌少症的蛋白组件及制备方法 |
| TWI774966B (zh) * | 2019-06-25 | 2022-08-21 | 生合生物科技股份有限公司 | 胚芽乳桿菌bcrc 910734用於提升老年個體的肌力以及治療肌肉減少症的用途 |
| US11872231B2 (en) | 2019-12-09 | 2024-01-16 | Nicoventures Trading Limited | Moist oral product comprising an active ingredient |
| US11969502B2 (en) | 2019-12-09 | 2024-04-30 | Nicoventures Trading Limited | Oral products |
| WO2021133962A1 (en) * | 2019-12-27 | 2021-07-01 | Grove Collaborative, Inc. | Confections for skin protection: compositions, methods for making, and applications thereof |
| BR112022019122A2 (pt) * | 2020-03-30 | 2022-11-08 | Gervais Danone Sa | Uso de uma composição de leite fermentado e método para suplementação dietética de metabólitos de bcaa |
| JP7742026B2 (ja) * | 2020-04-03 | 2025-09-19 | 三菱瓦斯化学株式会社 | 筋肉増強剤 |
| CA3188646A1 (en) * | 2020-07-02 | 2022-01-06 | Ponce De Leon Health Designated Activity Company | Compositions and methods for treating crp-mediated diseases |
| CN116209450B (zh) * | 2020-08-18 | 2024-08-09 | 食品科学有限责任企业 | 聚合乳清蛋白包封的抗氧化化合物及其制备方法 |
| FI129515B (en) * | 2020-11-06 | 2022-03-31 | Salarusta Oy | FOR USE IN THE PREVENTION AND / OR TREATMENT OF A DISEASE OR CONDITION RELATED TO THE DEGRADATION AND / OR DISTURBANCE OF THE DEGREE OF MONTOOSASE AND / OR INTEGRITY |
| CN112899204B (zh) * | 2021-03-19 | 2022-06-28 | 杭州百芮生物科技有限公司 | 一种益生菌冻干外壳复合保护剂及其应用 |
| CN113398144B (zh) * | 2021-07-27 | 2022-04-01 | 陈玉松 | 核苷酸混合物在制备预防或缓解老年肌少症制剂中的应用 |
| CN114029085B (zh) * | 2021-12-06 | 2024-02-27 | 中触媒新材料股份有限公司 | 一种烯烃环氧化催化剂及其制备方法和应用 |
| WO2023121696A1 (en) * | 2021-12-20 | 2023-06-29 | Schneider Todd C | Formulation and treatment for extended micronutrient therapy |
| WO2025151881A1 (en) * | 2024-01-12 | 2025-07-17 | Heh Research & Development Services, Inc. | Biologic enhancement formulation |
Family Cites Families (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2335215B2 (de) * | 1972-07-13 | 1979-04-05 | The Johns Hopkins University, Baltimore, Md. (V.St.A.) | Verwendung einer Mischung bei der Bekämpfung von zur Urämie führenden Nierenerkrankungen |
| GB1442154A (en) * | 1973-04-30 | 1976-07-07 | Walser M | Composition for promotion of protein synthesis and suppression of urea formation in the body |
| GB1444621A (en) * | 1973-04-30 | 1976-08-04 | Walser M | Composition for promotion of protein synthesis and suppression of urea formation in the body utilizing alpha-hydroxy-acid analogues of amino acids |
| GB1511302A (en) * | 1974-04-15 | 1978-05-17 | Univ Johns Hopkins | Pharmaceutical compositions comprising amino acid analogues |
| US4752619A (en) | 1985-12-23 | 1988-06-21 | The Johns Hopkins University | Nutritional supplement for treatment of uremia |
| SE8803144L (sv) * | 1988-09-07 | 1990-03-08 | Kabivitrum Ab | Energisubstrat |
| US5646187A (en) * | 1992-05-20 | 1997-07-08 | Ab Erik Vinnars | Use of alpha-ketoglutarate |
| SE9201584D0 (sv) * | 1992-05-20 | 1992-05-20 | Vinnars Erik Ab | Use of alpha-ketoglutarate |
| SE0201713D0 (sv) * | 2001-11-23 | 2002-06-06 | Gramineer Internat Ab | New methods and use III |
| US20040087490A1 (en) * | 2002-09-20 | 2004-05-06 | Troup John P. | Nutritional compositions |
| US8795693B2 (en) * | 2003-08-04 | 2014-08-05 | Foamix Ltd. | Compositions with modulating agents |
| US20050256192A1 (en) * | 2004-04-30 | 2005-11-17 | Gardiner Paul T | Nutritional composition for enhancing lean muscle stimulus, growth, strength and recovery, creating and prolonging intense muscle pumps, supporting endurance, strength, performance, size and stamina, providing a transducer effect for nitric oxide, increasing nutrient delivery and/or promoting increased vascular response in an individual |
| FI20045395A7 (fi) * | 2004-10-21 | 2006-04-22 | Oy Elmomed Ltd | Ravintoainelisä ja sen käyttö |
| AR053295A1 (es) * | 2005-05-23 | 2007-04-25 | Cadbury Adams Usa Llc | Composiciones que potencian el sabor y golosinas comestibles y productos de goma de mascar que los contienen |
| CN101179943B (zh) * | 2005-05-23 | 2013-06-26 | 卡夫食品环球品牌有限责任公司 | 填充液体的咀嚼型胶基糖组合物 |
| EP1774973A1 (en) * | 2005-10-12 | 2007-04-18 | Nutricia N.V. | Leucine rich composition |
| WO2007053943A1 (en) * | 2005-11-08 | 2007-05-18 | Multi Formulations Ltd. | The use of compositions comprising ketoacids and amino acids for increasing muscle mass and muscle performance |
| CA2633292C (en) * | 2005-12-16 | 2015-04-28 | N.V. Nutricia | Use of soluble dietary fibres against muscle wasting |
| US20100222282A1 (en) * | 2006-01-19 | 2010-09-02 | Entress Ab | Method of diagnosis and method of treatment |
| CA2642761A1 (en) * | 2006-02-23 | 2007-08-30 | Iomedix Sleep International Srl | Compositions and methods for the induction and maintenance of quality sleep |
| RU2420210C2 (ru) * | 2006-03-23 | 2011-06-10 | Нестек С.А. | Высококалорийная питательная добавка |
| RU2444355C2 (ru) * | 2006-04-04 | 2012-03-10 | Нестек С.А. | Способы лечения с применением цитруллина |
| CN101415414B (zh) * | 2006-04-04 | 2013-06-12 | 雀巢产品技术援助有限公司 | 瓜氨酸在制备治疗矫正脓毒症患者中精氨酸缺乏的药物中的用途 |
| PL379512A1 (pl) * | 2006-04-21 | 2007-10-29 | Sgp & Sons Ab | Nowe metody i ich zastosowanie |
| CA2660291C (en) * | 2006-08-09 | 2011-11-22 | The Iams Company | Methods of improving bone health and muscle health |
| FR2913885B1 (fr) * | 2007-03-22 | 2012-07-20 | Univ Paris Descartes | Utilisation de la citrulline pour le traitement des pathologies liees a une augmentation de la carbonylation des proteines |
| EP2192898A1 (en) * | 2007-09-11 | 2010-06-09 | Northern Innovations And Formulations Corp. | Composition and method for increasing the anabolic state of muscle cells |
| CA2610820A1 (en) * | 2007-12-12 | 2008-12-29 | Michele Molino | Method for maintaining physiological ph levels during intensive physical exercise |
| US20090156647A1 (en) * | 2007-12-12 | 2009-06-18 | Iovate T. & P. Inc. | Method for maintaining physiological pH levels during intensive physical exercise |
| WO2010002242A1 (en) * | 2008-07-02 | 2010-01-07 | N.V. Nutricia | Nutritional composition for improving muscle function and daily activity |
| JP2010105946A (ja) * | 2008-10-29 | 2010-05-13 | Nof Corp | 筋タンパク質増強剤及びこれを含む医薬品または食品 |
| WO2010108016A2 (en) * | 2009-03-18 | 2010-09-23 | Healthspan Solutions, Llc | Compositions and methods for sparing muscle in renal insufficiency and during hemodialysis |
| WO2010137944A1 (en) * | 2009-05-27 | 2010-12-02 | N.V. Nutricia | Treatment of hypercalcaemia |
| RU2012105901A (ru) * | 2009-07-20 | 2013-08-27 | Нестек С.А. | Способы снижения потери функционального состояния |
| CA2771283A1 (en) * | 2009-08-13 | 2011-02-17 | Nestec S.A. | Nutritional compositions including exogenous nucleotides |
| RU2012114832A (ru) * | 2009-09-14 | 2013-10-27 | Нестек С.А. | Питательные композиции для модулирования воспаления, содержащие экзогенный витамин к2 |
-
2012
- 2012-04-18 RU RU2013151083/13A patent/RU2013151083A/ru not_active Application Discontinuation
- 2012-04-18 CN CN2012800179097A patent/CN103458710A/zh active Pending
- 2012-04-18 MX MX2013012230A patent/MX2013012230A/es unknown
- 2012-04-18 JP JP2014505606A patent/JP2014511890A/ja active Pending
- 2012-04-18 AU AU2012244751A patent/AU2012244751A1/en not_active Abandoned
- 2012-04-18 EP EP12719307.6A patent/EP2699112A1/en not_active Withdrawn
- 2012-04-18 SG SG2013073465A patent/SG194028A1/en unknown
- 2012-04-18 CN CN2012800190607A patent/CN103476275A/zh active Pending
- 2012-04-18 CA CA2831165A patent/CA2831165A1/en not_active Abandoned
- 2012-04-18 SG SG2013071386A patent/SG193933A1/en unknown
- 2012-04-18 US US14/112,746 patent/US20140056862A1/en not_active Abandoned
- 2012-04-18 PH PH1/2013/502012A patent/PH12013502012A1/en unknown
- 2012-04-18 AU AU2012244749A patent/AU2012244749A1/en not_active Abandoned
- 2012-04-18 PH PH1/2013/501927A patent/PH12013501927A1/en unknown
- 2012-04-18 SG SG2013071626A patent/SG193938A1/en unknown
- 2012-04-18 MX MX2013012231A patent/MX2013012231A/es unknown
- 2012-04-18 EP EP12719308.4A patent/EP2699113A1/en not_active Withdrawn
- 2012-04-18 JP JP2014505604A patent/JP2014512371A/ja active Pending
- 2012-04-18 PH PH1/2013/502027A patent/PH12013502027B1/en unknown
- 2012-04-18 WO PCT/EP2012/057092 patent/WO2012143402A1/en not_active Ceased
- 2012-04-18 US US14/112,744 patent/US20140037604A1/en not_active Abandoned
- 2012-04-18 US US14/112,779 patent/US20140056863A1/en not_active Abandoned
- 2012-04-18 WO PCT/EP2012/057093 patent/WO2012143403A1/en not_active Ceased
- 2012-04-18 RU RU2013151087/13A patent/RU2013151087A/ru not_active Application Discontinuation
- 2012-04-18 CA CA2832150A patent/CA2832150A1/en not_active Abandoned
- 2012-04-18 CN CN201280019059.4A patent/CN103491804A/zh active Pending
- 2012-04-18 CA CA2832507A patent/CA2832507A1/en not_active Abandoned
- 2012-04-18 MX MX2013012228A patent/MX2013012228A/es unknown
- 2012-04-18 JP JP2014505603A patent/JP2014519483A/ja active Pending
- 2012-04-18 AU AU2012244750A patent/AU2012244750A1/en not_active Abandoned
- 2012-04-18 EP EP12715104.1A patent/EP2699110A1/en not_active Withdrawn
- 2012-04-18 US US14/112,785 patent/US20140044685A1/en not_active Abandoned
- 2012-04-18 BR BR112013026706A patent/BR112013026706A2/pt not_active IP Right Cessation
- 2012-04-18 JP JP2014505605A patent/JP2014512372A/ja active Pending
- 2012-04-18 RU RU2013151085/13A patent/RU2013151085A/ru not_active Application Discontinuation
- 2012-04-18 RU RU2013151090/13A patent/RU2013151090A/ru not_active Application Discontinuation
- 2012-04-18 CN CN2012800190556A patent/CN103476274A/zh active Pending
- 2012-04-18 WO PCT/EP2012/057094 patent/WO2012143404A1/en not_active Ceased
- 2012-04-18 BR BR112013026539A patent/BR112013026539A2/pt not_active IP Right Cessation
- 2012-04-18 SG SG2013073986A patent/SG194065A1/en unknown
- 2012-04-18 WO PCT/EP2012/057095 patent/WO2012143405A1/en not_active Ceased
- 2012-04-18 AU AU2012244748A patent/AU2012244748B2/en not_active Ceased
- 2012-04-18 CA CA2831001A patent/CA2831001A1/en not_active Abandoned
- 2012-04-18 PH PH1/2013/501926A patent/PH12013501926A1/en unknown
- 2012-04-18 EP EP12718133.7A patent/EP2699111A1/en not_active Withdrawn
-
2013
- 2013-10-18 MX MX2013012229A patent/MX2013012229A/es not_active Application Discontinuation
- 2013-11-15 ZA ZA2013/08606A patent/ZA201308606B/en unknown
- 2013-11-15 ZA ZA2013/08604A patent/ZA201308604B/en unknown
- 2013-11-15 ZA ZA2013/08605A patent/ZA201308605B/en unknown
- 2013-11-15 ZA ZA2013/08607A patent/ZA201308607B/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112013026539A2 (pt) | composições nutricionais que têm a-hica e a-cetoglutarato e métodos de uso das mesmas | |
| BR112014009265A2 (pt) | micelas de proteína de soro do leite contra atrofia muscular e sarcopenia | |
| BR112012022223A8 (pt) | Formulação de proteína concentrada, uso e método de preparação da mesma | |
| BR112013028907A2 (pt) | conjugados de proteína-agente ativo e método para preparar os mesmos | |
| UY35195A (es) | Composiciones y metodos para proteinas de accion prolongada | |
| PH12013500872A1 (en) | Salt(s) of 7-cyclopentyl-2 -(5-piperazin-1-yl-pyridin-2-ylamino)-7h-pyrrolo[2,3-d]pyrimidine-6-carboxylic acid dimethylamide and processes of making thereof | |
| WO2013002584A3 (ko) | 다중 타겟팅의 상승 효과를 유발하는 유효물질의 조합 및 그 용도 | |
| MX336187B (es) | Metodo para tratar el mal de parkinson. | |
| EA201491212A1 (ru) | Увлажняющая композиция, включающая аминопептидную смесь | |
| BRPI0913831B8 (pt) | peptídeo com a fórmula geral (i), seus estereoisômeros, suas misturas, ou seus sais cosmética ou farmaceuticamente aceitáveis, processo para a preparação de um peptídeo com a fórmula geral (i), seus estereoisômeros, suas misturas, ou seus sais cosmética ou farmaceuticamente aceitáveis e composição cosmética ou farmacêutica | |
| NZ608502A (en) | Polypeptides that bind to human complement component c5 | |
| BR112013031652A2 (pt) | métodos de tratamento para doenças retinais | |
| BR112014008036A2 (pt) | tratamento de rinite | |
| BR112015008297A2 (pt) | antagonistas de mglu2/3 para o tratamento de distúrbios autistas | |
| BR112014001017A2 (pt) | uso de um ou mais nucleotídeos para aperfeiçoar a estabilidade de calor de uma composição aquosa de caseína micelar; composição nutricional líquida; processo para o tratamento com calor de uma composição aquosa de caseína micelar; e método para prover nutrição a uma pessoa com necessidade desta | |
| CO2020004801A2 (es) | Uso de suplementos de aminoácidos para mejorar la síntesis de proteínas musculares | |
| EA201590601A1 (ru) | Применение pedf-производных полипептидов для лечения остеоартрита | |
| EA201591108A1 (ru) | Слитый гормон роста человека и альбумин, составы и их применения | |
| WO2011121607A3 (en) | Rasagiline and its pharmaceutically acceptable salts | |
| BR112014027213A2 (pt) | nova composição de alfentanil para o tratamento da dor aguda | |
| MX2011007108A (es) | Incrementadores de angiogenesis generados por derrame cerebral y usos de los mismos. | |
| MX2013006031A (es) | Formulacion liposomal de dalcetrapib. | |
| BR112015008964A2 (pt) | composições injetáveis estáveis contendo diclofenaco e tiocolquicosídeo | |
| BR112014001538A2 (pt) | composições farmacêuticas compreendendo 4-bromo-n-(imidazolidin-2-ilideno)-1h-benzimidazol-5-amina para tratamento de doenças retinais | |
| TH150715A (th) | องค์ประกอบทางโภชนาการที่มีอัลฟา-hica และอีไอโคซาเพนทาอีโนอิกแอซิด |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] | ||
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] | ||
| B15K | Others concerning applications: alteration of classification |
Ipc: A61K 31/7105 (2006.01), A23L 33/10 (2016.01), A23L |